365telugu.com online news,Mumbai, December 11, 2025:New research presented at ObesityWeek® 2025 indicates that a once-daily oral version of semaglutide — a popular weight-loss drug known by the brand name Wegovy® — may be as effective as the injectable form. These findings could significantly reshape obesity treatment in India, where oral medications are often preferred over injections.
Obesity continues to rise across India and is closely linked to diabetes, heart disease, and other severe health complications. Injectable semaglutide has already proven highly effective for weight loss and organ protection, but patient hesitation toward injections has limited its adoption.
Key Highlights of the Study
- Strong weight-loss outcomes:
Adults with overweight or obesity who took the 25 mg oral semaglutide pill achieved substantial weight loss. Indirect comparisons with earlier trials showed results on par with the injectable version. - Heart and metabolic health improvements:
Participants experienced reductions in blood pressure, cholesterol, and blood sugar levels, with the greatest benefits observed in those who lost at least 15% of their body weight. - Effective for women at all menopausal stages:
The pill delivered consistent weight-loss results for pre-, peri-, and post-menopausal women. - Better physical functioning:
Compared to placebo, most patients on the oral drug reported notable improvements in daily physical activity and overall functioning.
Indian Experts See a Major Opportunity
Indian endocrinologists believe that an oral version could remove a major barrier to treatment.
Dr. Ambrish Mithal, Group Chairman – Endocrinology & Diabetology at Max Healthcare, New Delhi, said:
“Semaglutide has revolutionized obesity treatment. It reduces weight and protects vital organs — from the heart to the kidneys. But many Indian patients hesitate to start injectable therapies. An equally effective pill could close this treatment gap and make obesity care far more accessible.”
He added that the drug’s established safety profile and proven benefits could encourage many patients to begin treatment earlier, helping prevent long-term complications.
Safety and Regulatory Status
The safety profile of the oral pill matched that of the injectable version, with mild to moderate gastrointestinal symptoms — such as nausea — being the most common side effects.
The 25 mg oral semaglutide pill is now under review by the US FDA and is not yet approved for use. If cleared, it would become the first oral GLP-1 therapy specifically for obesity, offering a more accessible long-term weight-management option for millions.